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In recent years, new therapeutic approaches that restore the ability of the immune system to
attack cancer cells have dramatically improved the outcome of various malignant tumors,
including melanoma and lung cancer. Ipilimumab, a monoclonal antibody that binds and
inhibits cytotoxic T-lymphocyte–associated antigen 4, and nivolumab, a monoclonal antibody
that blocks programmed cell-death protein 1, have been approved. As these treatments,
respectively, block T-cell inhibition and potentiate the activation of T cells, they may trigger
a number of neurologic immune-related adverse events,1–9 as illustrated here.
We describe a 71-year-old woman who was diagnosed in 2014 with stage IV small-cell lung
cancer and treated with 6 cycles of cisplatin/etoposide, followed by mediastinal and pro-
phylactic cranial irradiation. Because of tumor progression in the lung and liver, she received
a ﬁrst dose of nivolumab 1 mg/kg, followed by ipilimumab 3 mg/kg. On day 4 following
administration, she developed short-term memory deﬁcits that worsened over the next 5 days.
On admission, she was found to be disoriented in time and space and unable to recall any word
after 5 minutes. Autobiographic memory was preserved. She presented dysexecutive disorder
and was unable to read or write. MRI showed severe abnormalities in both hippocampi with
contrast-enhancing lesions (ﬁgure, A and B). A lumbar puncture showed lymphocytic pleo-
cytosis (white blood cells: 16 cells/μL; 87% lymphocytes, 12% monocytes, and 1% neu-
trophils, and increased CSF protein [1,145 mg/L]). Cytologic examination showed no
evidence of malignant cells. Extensive evaluation of blood and CSF revealed no evidence of
infection. The CSF was positive for anti-HU antibodies as well as for an uncharacterized
antibody against Purkinje cells. It was negative for other antibodies including CASPR2,
recoverin, Sox1, Titin, Zic4, DNER/Tr, amphiphysin, CV2/CRMP5, Ma2/Ta (PNMA2), Ri,
Yo, GAD65, NMDAR, GABAR, IgLON5, AMPAR2, DPPX, LGI1, glycine receptor, and
mGluR5. Nivolumab and ipilimumab were discontinued, and the patient was treated with
high-dose IV methylprednisolone (1,000 mg). After 5 days, steroids were progressively ta-
pered oﬀ; the patient, however, showed new clinical deterioration requiring introduction of
natalizumab and a new temporary increase in steroids. Thereafter, steroids could be weaned oﬀ
completely, and the patient showed neurologic improvement within 2 months of starting
natalizumab as well as marked improvement of the MRI ﬁndings (ﬁgure, C and D). The
patient is now able to recall 3/5 words at 5 minutes and can read and write. It is important to
note that despite having received a single dose of nivolumab/ipilimumab, the patient showed
a durable oncologic response.
This case illustrates several key points: (1) As evidenced by the presence of anti-Hu antibodies,
this patient had autoimmune encephalitis, which was likely exacerbated by the hyperactivation
of T cells, induced by nivolumab/ipilimumab: The timing of the onset of neurologic symptoms
strongly suggests an immune-related adverse event.10 Indeed, 3 other cases of paraneoplastic
encephalitis that developed early, i.e., within days of initiation of immune checkpoint inhibitors,
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were described.1,4 (2) Paraneoplastic encephalitis may present
with gadolinium enhancement on MRI.11 (3) Early recogni-
tion and treatment with immune-suppressive agents are
essential, as these patients may show marked improvement.
(4) More importantly, these side eﬀects are typically con-
trolled by high-dose steroids that act as potent immune
suppressors; however, steroids might also block the response
of the checkpoint inhibitors against cancer, thus impeding the
advantages that are precisely expected with the latter drugs.4
Natalizumab, a drug used for treating multiple sclerosis and
Crohn disease,12 might be an ideal drug to control paraneo-
plastic encephalitis induced by immune checkpoint inhibitors:
it is directed against the subunit α4 from a4β1 and a4b7-
integrins. Yet, these integrins, expressed at the surface
of lymphocytes, bind to vascular cell adhesion molecule-1 and
mucosal vascular addressin cell adhesion molecule-1, which
are expressed on endothelial cells of the blood-brain and
blood-gut barriers, respectively. This interaction decreases
leukocyte adhesion, attachment, and migration across these
barriers.13 However, the immune response in other com-
partments is not impeded. Therefore, we hypothesize that, in
our case, administration of natalizumab contributed to de-
crease the CNS inﬂammation without compromising the
immune reaction against systemic localizations of the cancer
and therefore allowed for continuation of immune checkpoint
inhibitor therapy, despite the development of paraneoplastic
encephalitis. In our patient, we believe that natalizumab played
a key role in controlling the autoimmune adverse event, as
steroids could be tapered well before the end of the half-life of
the checkpoint inhibitors. As these cases are extremely rare, we
propose to set up a registry to collect data on the presenting
symptoms, treatments, and outcomes of these patients.
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A 71-year-old woman was diagnosed in 2014 with small-cell lung cancer.
In 2016, she was treated with nivolumab and ipilimumab for systemic
recurrence. Four days later, she developed severe disorientation and short-
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normalize after 6 months of treatment with natalizumab (C and D).
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